Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients.

AIMS Six prospective real-world studies of antihypertensive treatment with valsartan-centric regimens were pooled to (1) examine the effectiveness of ∼90 days of second- or later-line valsartan treatment in hypertensive patients with known comorbidities; and (2) identify physician and patient-related determinants associated with systolic (SBP) and diastolic blood pressure (DBP) outcomes in these patients. METHODS AND MATERIALS Pooled analysis of an evaluable sample of 11,999 hypertensive patients with known comorbidities treated ∼90 days with valsartan-centric regimens. We applied hierarchical linear and logistic regression models to identify determinants of blood pressure (BP) outcomes and a potential physician class effect. RESULTS Valsartan regimens resulted in mean(SD) systolic (SBP) and diastolic (DBP) reductions of 18.0(15.8)mmHg and 9.5(10.1)mmHg, respectively, at ∼90 days; yielding SBP, DBP and combined SBP/DBP control rates of 44.0%, 67.2% and 39.3%, respectively. About a quarter of the variance in 90-day BP values was attributable to a physician class effect. BP outcomes declined with physicians' increasing years in practice and being male. At the patient-level, BP outcomes declined with SBP and DBP at diagnosis; diabetes; higher cholesterol and BMI; lower valsartan and HCTZ doses; and concomitant anti-hypertensives. Older age was associated with improved DBP. A proxy of physician vigilance, cardiovascular disease history was associated with improved BP outcomes; as were patient adherence and higher doses of valsartan in combination with HCTZ. CONCLUSIONS Valsartan-centric regimens have significant BP lowering benefits in this pooled sample of patients with known comorbidities. Many observed determinants of BP outcomes are modifiable or manageable.